The International Society for Pharmacoeconomics and Outcomes Research

The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) will hold its 22nd Annual International Meeting in Boston, Massachusetts, from May 20-24, 2017. This year's meeting, Evidence and Value in a Time of Social and Policy Change, will bring payers, researchers, and other stakeholders together to learn about drug development and regulatory issues in today's rapidly-changing healthcare environment. Sign up for our daily e-mail blasts on our registration page, and check back here during the conference for the full coverage.

Coverage

Value Assessment Frameworks Should Represent a Spectrum of Patient Preferences
   |    ISPOR
Ilene Hollin, PhD, MPH, the National Pharmaceutical Council and University of Southern California Schaeffer Center’s Postdoctoral Health Policy Fellow, discusses what needs to be included in the next generation of value assessment frameworks in order to best identify value that is representative of all patient preferences.
Dr Michael Sherman: US Can Learn From Other Countries on Paying for Value
   |    ISPOR
The United States can learn from other countries about paying for value by acknowledging the effects of our choices and setting limits within value frameworks to manage drug costs, said Michael Sherman, MD, chief medical officer at Harvard Pilgrim Health Care.
Dr Patricia Danzon: Learning From European Health Systems
   |    ISPOR
The United States can benefit from taking and adapting certain elements of European countries’ systems and methods of assessing value, says Patricia Danzon, PhD, the Celia Moh Professor at The Wharton School, University of Pennsylvania.
Dr Ilene Hollin: One-Size-Fits-All to Value Doesn't Work
   |    ISPOR
A one-size-fits-all approach to value is impossible in the US healthcare system, but a pluralistic approach is extremely complex to implement, says Ilene Hollin, PhD, MPH, the National Pharmaceutical Council and University of Southern California Schaeffer Center’s Postdoctoral Health Policy Fellow.
Dr Michael Sherman on Harvard Pilgrim's Work With Value Frameworks
   |    ISPOR
Michael Sherman, MD, chief medical officer at Harvard Pilgrim Health Care, discusses how Harvard Pilgrim uses value framework during formulary deliberations to help make decisions, despite the fact that they only cover certain disease states right now.
Dr Patricia Danzon Highlights European Examples of Restraining Drug Prices
   |    ISPOR
A combination of different countries’ health systems can set an example for the United States to follow in efforts to restrain the ongoing increases in drug prices, explains Patricia Danzon, PhD, the Celia Moh Professor at The Wharton School, University of Pennsylvania.
Dr Steve Pearson on Balancing Cost and Effectiveness of New Therapies
   |    ISPOR
When determining whether new treatments are cost-effective, it is important to understand how a therapy can improve the patient’s quality of life, explained Steve Pearson, MD, MSc, president of the Institute for Clinical and Economic Review. Not all outcome measures, such as surrogate outcomes, correspond to the quality of life and survival benefits that are important to patients.
Dr Ilene Hollin Outlines Differing Definitions of Value
   |    ISPOR
Patients, payers, and providers all view value in different ways, and they all need to be taken into account in value frameworks, said Ilene Hollin, PhD, MPH, the National Pharmaceutical Council and University of Southern California Schaeffer Center’s Postdoctoral Health Policy Fellow.
Compendia
Adult ADHD Compendium
COPD Compendium
Dermatology Compendium
Diabetes Compendium
GI Compendium
Hematology Compendium
Immuno-oncology Compendium
Lipids Compendium
MACRA Compendium
Oncology Compendium
Pain Compendium
Reimbursement Compendium
Rheumatoid Arthritis Compendium
Know Your News
HF Compendium
Managed Care PODCAST
Upcoming Partner Events
October 16-17, 2017
Washington, D.C.
October 24-25, 2017
San Francisco, CA
$vacMongoViewPlus$